麦澜德(688273.SH)业绩快报：2025年归母净利润1.02亿元，同比增长0.47%

Core Viewpoint - The company reported its preliminary financial results for the fiscal year 2025, showing mixed performance with slight revenue growth but declines in profit metrics [1] Financial Performance - Total revenue for the reporting period reached 432 million yuan, representing a year-on-year increase of 1.66% [1] - Operating profit was 105 million yuan, down 8.53% compared to the previous year [1] - Total profit amounted to 104 million yuan, reflecting a decrease of 16.65% year-on-year [1] - Net profit attributable to shareholders of the parent company was 102 million yuan, showing a modest increase of 0.47% [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses was approximately 80.1 million yuan, down 2.32% year-on-year [1] Asset and Equity Position - At the end of the reporting period, total assets stood at 1.558 billion yuan, an increase of 0.71% from the beginning of the year [1] - Equity attributable to shareholders of the parent company was 1.347 billion yuan, up 2.67% from the start of the year [1] - The share capital remained stable at 100 million shares, with net asset value per share at 13.47 yuan, reflecting a growth of 2.67% [1] Business Development - The company has been focusing on strengthening brand development and optimizing channels to lay a solid foundation for business growth [1] - The reproductive rehabilitation product segment maintained a solid competitive advantage, achieving steady growth [1] - To consolidate its technological edge and effectively respond to market changes, the company has continued to increase investments in R&D and marketing [1]